Sputnik V gets emergency use authorisation in India
NEW DELHI [Maha Media]: The Central drug regulator, DCGA has approved emergency use authorisation of the Russian Vaccine, Sputnik V. It has now become the third vaccine to get emergency use authorisation from the drug regulator after Covishield and Covaxin.
This was informed by the Russian Direct Investment Fund, RDIF which is a sovereign fund body established by the Russian Government and is engaged with the work of worldwide supply of the SPUTNIK V Vaccine. The Vaccine was developed by Gamaleya National Research Institute of Epidemiology and Microbiology last year in Russia.
The clinical trials of SPUTNIK V in India is being done by Dr Reddy's Lab. The Hyderabad based, multinational Indian pharma company, Dr. Reddy's Lab has also inked an agreement with the Russian Direct Investment Fund, RDIF for supply of the Russian vaccine in India. The Subject Expert Committee of the Indian drug regulator had yesterday recommended SPUTNIK V for emergency use authorisation.
The vaccine has displayed robust results in its clinical trials in the country. RDIF has claimed an effectiveness of 91.6 per cent for the Sputnik V vaccine. Dr Reddy's had applied for emergency use of Sputnik-V in February this year.